 |
323 Products |  |
957 Diseases | | 323 Products |
|
1268 Trials |  |
64372 News |  |
| «12...739740741742743744745746747748749750751» |
- | Arzerra (ofatumumab) / Novartis, Genmab
Enrollment open: Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 15, 2011
P2, N=34, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab (clinicaltrials.gov) - Dec 14, 2011
P3, N=250, Completed, Sponsor: GlaxoSmithKline
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial termination: Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia (clinicaltrials.gov) - Dec 14, 2011
P4, N=54, Terminated, Sponsor: Allergan
Not yet recruiting --> Recruiting Completed --> Terminated; Study was terminated early due to difficulties with patient recruitment
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial initiation date: Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia (clinicaltrials.gov) - Dec 14, 2011
P4, N=54, Terminated, Sponsor: Allergan
Completed --> Terminated; Study was terminated early due to difficulties with patient recruitment Initiation date: Jan 2007 --> Jun 2007
- |||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion: Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia (clinicaltrials.gov) - Dec 14, 2011
P4, N=145, Completed, Sponsor: Allergan
Initiation date: Jan 2007 --> Jun 2007 Active, not recruiting --> Completed
- ||| Anoro Ellipta (umeclidinium/vilanterol) / Innoviva, GSK
New P3 trial: Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD (clinicaltrials.gov) - Dec 12, 2011
P3, N=24, Recruiting, Sponsor: Queen's University
- Promacta (eltrombopag) / Novartis
New P1/2 trial, Metastases: Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia (clinicaltrials.gov) - Dec 12, 2011
P1/2, N=1, Terminated, Sponsor: Duke University
- | Arzerra (ofatumumab) / Novartis, Genmab
Enrollment open, Combination therapy: Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide (clinicaltrials.gov) - Dec 12, 2011
P1/2, N=36, Recruiting, Sponsor: Thomas Jefferson University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Rotarix (rotavirus vaccine) / GSK
Trial completion: A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar (clinicaltrials.gov) - Dec 11, 2011
P3, N=1375, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Benlysta (belimumab) / GSK
P2 data, Trial termination: Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Dec 8, 2011
P2, N=56, Terminated, Sponsor: Human Genome Sciences Inc.
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Sponsor terminated study for business reasons.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P2/3 trial: Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy (clinicaltrials.gov) - Dec 8, 2011
P2/3, N=60, Active, not recruiting, Sponsor: Hospital Vall d'Hebron
- | Galafold (migalastat) / Amicus
New P1 trial: Migalastat Food Effect Study (clinicaltrials.gov) - Dec 8, 2011
P1, N=20, Completed, Sponsor: Amicus Therapeutics
- | GSK 2336805 / J&J
Trial completion: Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults (clinicaltrials.gov) - Dec 8, 2011
P1, N=28, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated; Sponsor terminated study for business reasons. Active, not recruiting --> Completed
- ||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion: Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence (clinicaltrials.gov) - Dec 7, 2011
P3, N=548, Completed, Sponsor: Allergan
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Promacta (eltrombopag) / Novartis
New P2 trial: A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia (clinicaltrials.gov) - Dec 6, 2011
P2, N=25, Active, not recruiting, Sponsor: Peter MacCallum Cancer Centre, Australia
- ||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion: Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence (clinicaltrials.gov) - Dec 6, 2011
P3, N=557, Completed, Sponsor: Allergan
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tice BCG (live attenuated bacillus Calmette-Guerin) / Merck (MSD), Texas A&M University, Zumagev (astuprotimut-R) / GSK
New P1 trial: BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients (clinicaltrials.gov) - Dec 5, 2011
P1, N=24, Enrolling by invitation, Sponsor: Patrice Jichlinski
- ||||| Xeomin (incobotulinumtoxinA) / Merz Pharma
New P4 trial, Head-to-Head: Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin (clinicaltrials.gov) - Dec 4, 2011
P4, N=424, Recruiting, Sponsor: Merz Pharmaceuticals, LLC
- ||| Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
Enrollment change, Head-to-Head: Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults (clinicaltrials.gov) - Dec 1, 2011
P4, N=213, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=495 --> 213
- ||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment change: A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity (clinicaltrials.gov) - Dec 1, 2011
P3, N=109, Completed, Sponsor: GlaxoSmithKline
N=495 --> 213 N=168 --> 109
- ||||| Medytoxin (botulinum toxin type A) / Medytox
New P2 trial: Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines (clinicaltrials.gov) - Dec 1, 2011
P2, N=121, Completed, Sponsor: Medy-Tox
- ||| Synflorix (10-valent pneumococcal conjugate vaccine) / GSK
New P1 trial, Pneumococcal vaccines: Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers (clinicaltrials.gov) - Dec 1, 2011
P1, N=61, Completed, Sponsor: GlaxoSmithKline
- |||||||||| Benlysta (belimumab) / GSK
New P3 trial: BLISS-SC: A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Nov 30, 2011
P3, N=816, Active, not recruiting, Sponsor: Human Genome Sciences Inc., a GSK Company
- Promacta (eltrombopag) / Novartis
New P2 trial: Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Nov 30, 2011
P2, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
- ||||| Bexxar (iodine I 131 tositumomab) / GSK, Rituxan (rituximab) / Roche
New P1/2 trial, Metastases: Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 30, 2011
P1/2, N=96, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- | Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
New P1 trial: Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination (clinicaltrials.gov) - Nov 30, 2011
P1, N=30, Completed, Sponsor: GlaxoSmithKline
- | GSK 1440115 / GSK
Trial completion: Single Dose Study of GSK1440115 in Patients With Asthma (clinicaltrials.gov) - Nov 30, 2011
P1, N=12, Completed, Sponsor: Accenture
N=168 --> 109 Recruiting --> Completed
- | Benlysta (belimumab) / GSK
New P2 trial: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Nov 27, 2011
P2, N=42, Recruiting, Sponsor: GlaxoSmithKline
- | Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Roche
New P2 trial: Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients (clinicaltrials.gov) - Nov 27, 2011
P2, N=77, Recruiting, Sponsor: Polish Lymphoma Research Group
- | Promacta (eltrombopag) / Novartis
New P1 trial: Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Nov 27, 2011
P1, N=12, Completed, Sponsor: Nordic MDS Group
- Potiga (retigabine) / Bausch Health, GSK
New P1 trial: Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite (clinicaltrials.gov) - Nov 27, 2011
P1, N=8, Completed, Sponsor: GlaxoSmithKline
- |||||||||| Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
New P3 trial: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) (clinicaltrials.gov) - Nov 24, 2011
P3, N=1315, Completed, Sponsor: Sanofi Pasteur MSD
- ||| GSK2245035 / GSK
New P1 trial, IO biomarker: An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics. (clinicaltrials.gov) - Nov 22, 2011
P1, N=61, Completed, Sponsor: GlaxoSmithKline
- |||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion: Radial Diffusion of the Botulinum Toxin Type A (Botox (clinicaltrials.gov) - Nov 21, 2011
P4, N=64, Completed, Sponsor: Ivo Pitanguy Institute
Recruiting --> Completed Recruiting --> Completed
- ||||| Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
Enrollment change: Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine (clinicaltrials.gov) - Nov 20, 2011
P3, N=252, Completed, Sponsor: Novartis
Recruiting --> Completed N=86 --> 252
- ||| Galafold (migalastat) / Amicus
New P3 trial: Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease (clinicaltrials.gov) - Nov 20, 2011
P3, N=20, Recruiting, Sponsor: Amicus Therapeutics
- || Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
New P3 trial: Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing COPD maintenance therapy alone in subjects with Chronic Obstructive Pulmonary Disease. (EUDRACT) - Nov 20, 2011
P3, N=4232, Ongoing, Sponsor: GlaxoSmithKline Research & Development Ltd
- | Horizant (gabapentin enacarbil XR) / Azurity Pharma, Astellas, GSK
New P1 trial: Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine (clinicaltrials.gov) - Nov 20, 2011
P1, N=18, Completed, Sponsor: XenoPort, Inc.
- ||| GSK1995057 / GSK
New P1 trial: Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects. (clinicaltrials.gov) - Nov 20, 2011
P1, N=56, Completed, Sponsor: GlaxoSmithKline
- | GSK239512 / GSK
Enrollment change: Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia (clinicaltrials.gov) - Nov 17, 2011
P2, N=50, Completed, Sponsor: GlaxoSmithKline
N=86 --> 252 N=80 --> 50
- ||||| Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
Enrollment closed: Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls (clinicaltrials.gov) - Nov 17, 2011
P3, N=1447, Active, not recruiting, Sponsor: GlaxoSmithKline
N=80 --> 50 Recruiting --> Active, not recruiting
- | GSK239512 / GSK
Trial completion: Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia (clinicaltrials.gov) - Nov 17, 2011
P2, N=50, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Tanzeum (albiglutide) / GSK
New P2 trial: Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Nov 17, 2011
P2, N=41, Completed, Sponsor: GlaxoSmithKline
- ||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion: GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis (clinicaltrials.gov) - Nov 17, 2011
P3, N=152, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- clozapine / Generic mfg.
Enrollment change: ATOMICS: Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia (clinicaltrials.gov) - Nov 16, 2011
P=N/A, N=8, Terminated, Sponsor: North Shore Long Island Jewish Health System
Active, not recruiting --> Completed N=12 --> 8
- | GSK2339345 / GSK
New P1 trial: FTIH: The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects (clinicaltrials.gov) - Nov 16, 2011
P1, N=31, Completed, Sponsor: GlaxoSmithKline
- ||| Fluarix (influenza virus trivalent vaccine) / GSK
Enrollment change: Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age (clinicaltrials.gov) - Nov 13, 2011
P2, N=437, Completed, Sponsor: GlaxoSmithKline
N=12 --> 8 N=320 --> 437
- | Meridia (sibutramine) / AbbVie, Xenical (orlistat) / Roche, GSK
New P4 trial: The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Nov 13, 2011
P4, N=200, Active, not recruiting, Sponsor: Aristotle University Of Thessaloniki
- |||| Incruse Ellipta (umeclidinium) / GSK
Trial completion: A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Nov 13, 2011
P2, N=163, Completed, Sponsor: GlaxoSmithKline
N=320 --> 437 Active, not recruiting --> Completed
- |||| batefenterol (GSK961081) / GSK
Trial completion: A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Nov 13, 2011
P2, N=437, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed